Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $103.85 USD
Change Today +3.45 / 3.44%
Volume 464.1K
ESPR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 5:20 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

esperion therapeutics inc (ESPR) Snapshot

Open
$100.73
Previous Close
$100.40
Day High
$104.88
Day Low
$99.13
52 Week High
03/19/15 - $118.95
52 Week Low
05/5/14 - $12.76
Market Cap
2.3B
Average Volume 10 Days
650.7K
EPS TTM
$-2.24
Shares Outstanding
22.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ESPERION THERAPEUTICS INC (ESPR)

Related News

No related news articles were found.

esperion therapeutics inc (ESPR) Related Businessweek News

No Related Businessweek News Found

esperion therapeutics inc (ESPR) Details

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, as well as to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies. The company’s products also comprise 4WF, a synthetic apoA-I therapy for treating patients with acute coronary syndrome has completed Phase 2a clinical studies; and ESP41091, which is in pre-clinical trials for lipid metabolism and body weight reduction. Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.

21 Employees
Last Reported Date: 03/10/15

esperion therapeutics inc (ESPR) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $450.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $150.0K
Senior Advisor to Chief Executive Officer
Total Annual Compensation: $335.0K
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2014.

esperion therapeutics inc (ESPR) Key Developments

Esperion Therapeutics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM

Esperion Therapeutics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Esperion Therapeutics, Inc. - Special Call

To discuss positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy.

Esperion Therapeutics, Inc. Announces Positive Top-Line Results from ETC-1002-009, a Phase 2b study

Esperion Therapeutics, Inc. announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy. Top-line results showed the 12-week study met its primary endpoint of greater LDL-cholesterol lowering from baseline with ETC-1002 compared with placebo. ETC-1002-treated patients achieved 17 and 24% incremental reductions in LDL-cholesterol at doses of 120 mg and 180 mg, respectively, compared with patients on stable statin therapy alone. These reductions were significantly different from placebo, occurred within the first two weeks of initiating therapy, and continued throughout the treatment period. Consistent with prior studies, ETC-1002 demonstrated reductions of up to 30% in high-sensitivity C-reactive protein (hsCRP), an important marker of inflammation in coronary disease. ETC-1002-treated patients achieved LDL-cholesterol lowering of up to an additional 24% at 12 weeks compared with 4% in the placebo group. Levels of hsCRP were reduced by up to 30% with ETC-1002. ETC-1002 was safe and well tolerated, with no muscle-related AEs or ETC-1002-related SAEs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $103.85 USD +3.45

ESPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESPR.
View Industry Companies
 

Industry Analysis

ESPR

Industry Average

Valuation ESPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 15.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit www.esperion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.